The objective of the present study was to use pharmacokinetic-pharmacodynamic modelling to characterize the effects of chemotherapy on the granulopoietic system and to predict the absolute neutrophil counts (ANCs) for patients with chemotherapyinduced neutropenia treated with filgrastim and pegfilgrastim.
Introduction
Granulocyte colony-stimulating factor (G-CSF) stimulates the activation, proliferation, differentiation, maturation and survival of neutrophil precursor cells in the bone marrow as well as enhancing mature neutrophil cell function. G-CSF exerts its effect by binding to a specific cell surface receptor (G-CSFR) that is present on cells of the neutrophilic granulocyte lineage; subsequently, the G-CSF/ G-CSFR complex is internalized and degraded. Filgrastim is a recombinant methionine human G-CSF, and pegfilgrastim is a long-acting form of filgrastim produced by covalently binding a 20 kD polyethylene glycol molecule to the N-terminal methionine residue. Both molecules are exogenous haematopoietic growth factors with biological activity that is identical to that of endogenous G-CSF and are used therapeutically for the treatment of inherited or chemotherapy-induced neutropenia (CIN) as well as for the mobilization of peripheral blood progenitor cells for transplantation. Filgrastim and pegfilgrastim can be administered by either intravenous (IV) or subcutaneous (SC) injections and exhibit complex nonlinear pharmacokinetics (PK) because they are largely cleared by binding to G-CSFRs on neutrophils (although filgrastim also undergoes renal clearance). The absolute neutrophil counts (ANCs) increase in response to treatment following both routes of administration [1] [2] [3] [4] .
Physiology-based models for chemotherapy-induced myelosuppression have been developed for the optimization of febrile neutropenia prevention during antitumour therapy, and pharmacodynamics (PD)-mediated drug disposition models have been introduced to allow simultaneous analysis of the serum G-CSF concentration with ANC-time profiles. These models describe the nonlinear PK and feedback regulation for exogenous G-CSF, as well as G-CSF clearance by neutrophils and their differential effects on neutrophil populations in the blood [5] [6] [7] [8] .
The present work addressed the adaptation of such models to conduct integrated PKPD analysis, describing the long-term effects of both filgrastim and pegfilgrastim treatments on granulopoiesis, either alone in healthy adult subjects or in adult and paediatric cancer patients with CIN.
Methods

Studies and data
Filgrastim and pegfilgrastim serum concentrations and ANC time courses were obtained from 10 in-house studies -two studies in healthy adults following filgrastim and pegfilgrastim IV and SC administration, two studies in healthy adults following filgrastim and pegfilgrastim SC administration, and four studies in adult and two studies in paediatric subjects with cancer undergoing chemotherapy following filgrastim and pegfilgrastim SC administration (Table 1 ). All studies were sponsored by Amgen Inc. and conducted in accordance with principles for human experimentation, as defined in the Declaration of Helsinki and International Conference on Harmonisation Good Clinical Practice guidelines. The lower limit of quantitation for filgrastim and pegfilgrastim serum concentrations was different between studies and ranged from 0.03 ng ml -1 to 0.16 ng ml -1 . All studies were approved by their respective institutional review boards, and informed consent was obtained from each subject. For healthy adults, SC administration data were selected for formal model development and covariate analysis. Subjects treated IV with filgrastim (375 μg kg -1 and 750 μg kg -1 ) and pegfilgrastim (30 μg kg -1 and 60 μg kg -1 ) were used as comparators for equivalent SC regimens. Three SC administration data subsets were created to inform the different stages of model development, resulting in datasets A, B and C. All datasets included the first chemotherapy cycle owing to the challenging implementation of intercycle variability and computational times. Dataset A was the primary dataset for structural model development and included all data in healthy subjects and the first chemotherapy cycle in adult subjects with cancer on different chemotherapy regimens (n = 703; 6830 PK and Table 1 Summary of clinical studies in adults and paediatric patients with or without chemotherapy 9213 PD observations). Dataset B included all data in healthy subjects and the first chemotherapy cycle in adults and paediatric subjects with cancer on chemotherapy (n = 755; 7575 PK and 10 305 PD observations). As dataset B included data from paediatric patients, these data were used for additional covariate analysis. Dataset C included all data in healthy subjects and all chemotherapy cycles in adult subjects with cancer on chemotherapy (n = 703; 8794 PK and 27 203 PD observations). Following model development and initial covariate analysis using dataset A, models were run on datasets B (including paediatrics) and C (multiple cycles in all subjects), separately. A good similitude was found for the estimated parameters fit between dataset B and datasets A and C (results not shown). Thus, the final covariate selection was based on dataset B, and the model fit to the first cycle data was deemed as the final reference model.
Model structure
The structure of the final model is depicted in Figure 1 , and the model code is provided in the Supporting Information.
The model was used to account for the disposition of filgrastim and pegfilgrastim, as well as ANC levels in the presence or absence of a corticosteroid and/or chemotherapy treatment. This model structure is an adaptation of a previously published G-CSF model, for which the PK of filgrastim is governed by both systemic-and PD-mediated effects [8] .
The granulopoiesis system and treatment model quantifies four major components: (i) ANC homeostasis (i.e. neutrophil maturation) and dynamics; (ii) G-CSF disposition and its effects on granulopoiesis; (iii) the chemotherapy effect in depleting ANC precursors; and (iv) corticosteroid stimulation of ANC levels. The effect of filgrastim and pegfilgrastim on ANCs was based on a model for stimulation of neutrophil production and maturation in the bone marrow. The effect of neutrophils on filgrastim or pegfilgrastim disposition was based on a drug receptor-binding model that assumed quasi-equilibrium between the free species and the G-CSF/G-CSFR complex [9] . The kinetics of the chemotherapy and corticosteroid effects was modelled using the kinetic-pharmacodynamic (KPD) approach [10] , while also modulating for the stimulation parameters in the ANC dynamics model (including stimulation of neutrophil precursor death in the mitotic phase for chemotherapy, stimulation of neutrophil production and transit time for corticosteroid effects).
G-CSF PK disposition model. The PK of filgrastim and pegfilgrastim was described by a PD-mediated model, specifically for drugs exhibiting target-mediated drug disposition [9, [11] [12] [13] . G-CSF (filgrastim or pegfilgrastim) was administered into a depot compartment (A SC ), with a bioavailability of F SC , and entered into systemic circulation at the first-order rate (K SC ; h À1 ). The relative bioavailability was fixed to 1 for filgrastim and estimated for pegfilgrastim. Once in the systemic circulation, filgrastim formed complexes with G-CSFR on the surface of neutrophils, and this interaction was governed by the total amount of drug present in the serum (D T ; nM), the total concentration of available receptors (R T ; nM) and the affinity of G-CSF for G-CSFR (K D ). Free drug (D) was assumed to be eliminated from 
The G-CSFR-bound filgrastim was internalized according to a first-order process governed by the rate constant (K INT ; h À1 ). The free drug (D; nM) and drug/G-CSFR complex (RD; nM) concentrations were calculated assuming quasi-equilibrium between the total drug concentration (D T /V D ) and available receptors (R T ) in the serum [9] . The equations governing this PK model are shown below:
The total mass of exogenous drug in the system was tracked according to the following equation:
Neutrophil maturation and response to treatment. The ANC dynamics component of the model was represented by a catenary chain of four compartments to mimic the production and maturation of neutrophils in the bone marrow [5-8, 14, 15] . The receptors were tracked through the production, maturation and turnover of neutrophils, which were represented by stem cells (R SM ), cells undergoing mitosis (R MT ) and the two precursor states in the bone marrow (R PM1 and R PM2 ). The neutrophil precursors were produced at a zero-order rate constant (k p ; nM h -1 ) and transited from compartment to compartment with firstorder rate constants (k tr ; h À1 ). The value for k tr was fixed to 4/120 h À1 (i.e. 5 days) based on the maturation time of neutrophils in the bone marrow [16] . In blood, the neutrophils were eliminated at a first-order rate constant (k c ; h À1 ). The value for k c was fixed to 1/6 h À1 or 0.693/6 h À1 , corresponding to a 6-h life span or half-life of the neutrophils in the blood [17, 18] . This component represented the concentration of G-CSFRs expressed in nanomolar units. To translate the receptor concentration into an ANC, the concentration was divided by an estimated scaling factor (S R ; nM/[× 10 9 cells l -1 ]), which represents the cellular receptor density. The equations describing neutrophil dynamics are shown below:
Figure 1 Final pharmacokinetic-pharmacodynamic structural model of filgrastim and pegfilgrastim, as well as their effects on absolute neutrophil count (ANC) in the absence or presence of a corticosteroid chemotherapy treatment. The final model is composed of four components -the neutrophil dynamics component, the filgrastim and pegfilgrastim component (top right), the chemotherapy component (bottom left) and the corticosteroid component (top left). CHM, chemotherapy compartment; CHMSL, slope relating the chemotherapy elimination rate with the first-order elimination rate constant of receptors from the mitosis compartment; CL D , clearance of filgrastim or pegfilgrastim; CRT 50 , elimination rate constant of corticosteroids that gives 50% stimulation of neutrophil production and transit rate; FSC, bioavailability after subcutaneous administration; G-CSF, granulocyte colony-stimulating factor; k C , elimination rate of neutrophils from the blood into the tissues; k CHM , elimination rate of chemotherapy from the virtual compartment; k CRT , elimination rate of corticosteroids from the virtual compartment; K D , dissociation constant of the complex filgrastim receptor or pegfilgrastim receptor; k int , rate constant of internalization; k P , production rate of receptors; k SC , absorption rate after subcutaneous administration; k TR , transit rate between the receptor compartments in the bone marrow; LAG CRT , also known as LAG8, lag-time of the corticosteroids; LAG CHM , also known as LAG9, lag-time of the chemotherapy; R MT , mitotic cells; R PM1 , first post-mitotic precursors; R PM2 , second post-mitotic precursors; R SM , neutrophil stem cells; SR, scaling factor representing cellular receptor density on ANC; ST 1 , process of stimulating neutrophil production; ST 2 , process of stimulating neutrophil maturation; V D , volume of distribution of filgrastim or pegfilgrastim
The effect of filgrastim and pegfilgrastim was described as stimulating neutrophil production (ST 1 ) and maturation (ST 2 ), which were driven by the fraction of bound receptors. The loss of mitotic cells due to chemotherapy is accounted for by STM, where STM 1 and STM 2 represent the maximum stimulatory effect for ST 1 and ST 2 , respectively (Equations 10 and 11).
The initial values of the nonzero states in homeostasis were calculated using the equations below:
The number of receptors per cell was assumed to be constant, and the relationship between receptor concentration (R T ; nM) and ANC levels was defined by the parameter S R , as described below:
A baseline parameter (BSL D ; nM) was estimated to account for the endogenous concentration of G-CSF.
CIN.
As mentioned previously, the kinetics of the chemotherapy effect on granulopoiesis was accounted for by using a KPD approach [10] . This effect was implemented as a stimulation of the elimination rate of neutrophil precursors (STM) at the mitotic stage, which was proportional to the chemotherapy output rate (k CHM × CHM) from a virtual CHM compartment. CHMSL (mg À1 ) was the parameter relating the rate of change in chemotherapeutic agent to loss of receptors in the mitotic compartment (Equations 15 and 16).
A delay parameter (Lag 9 ; h) was added to account for the temporal delay between the administration of chemotherapy and its effect on cells in the mitotic compartment.
Corticosteroid stimulation of ANC levels. A KPD model was also used to account for the kinetics of the corticosteroid treatment effect on granulopoiesis. In all subjects, an arbitrary dose of 1 mg was administered as a bolus 24 h before chemotherapy with lag time (Lag 8 ; h) in a virtual corticosteroid (CRT) compartment. This CRT effect would decline exponentially at a rate k CRT (h À1 ), as described below:
The effect of the corticosteroids was implemented as an E max model. This model was driven by the corticosteroid output rate (k CRT × CRT) through the modulation of progenitor production and precursor maturation rates by modifying ST 1 and ST 2 :
The term CRT 50 represented the corticosteroid output rate that gave 50% of the maximum effect. When no corticosteroid was present, CRT was set to zero and the relationship simplified to the previously defined equations for ST 1 and ST 2 (Equations 10 and 11, respectively).
Software
Temporal profiles for filgrastim and pegfilgrastim concentrations and ANC were analysed by nonlinear mixed-effects modelling using the SAEM algorithm within Monolix version 4.3.0 (Lixoft, Orsay, France) running under MATLAB version 7.12.0.635 (R2011a or b; MathWorks Inc., Natick, MA, USA). Evaluation of analysis outputs was further processed within Monolix or R version 2.12.2 (www.http://cran.r-project.org). Graphical and all other statistical analyses were processed with R version 2.12.2 running under RStudio version 0.98.0501. Simulations were performed with Simulo version 5.3.3 (SGS Exprimo), a JAVA-based software that creates and executes R scripts.
Statistical model
Interindividual variabilities (IIVs) in the model parameters were assumed to be log-normally distributed. Their magnitudes were thereafter expressed as a % coefficient of variation. Residual variability was described using an additive error model in the log domain for both PK and PD endpoints.
Model evaluation
Model fit was evaluated using standard goodness-of-fit criteria (including normalized prediction distribution errors vs. population predictions and time), reduction in the objective function value and acceptable precisions on estimates. Initially, the model predictive performance was evaluated internally using the prediction-corrected visual predictive checks (pcVPC) technique [19] and the ability of the model to predict the level of neutropenic nadir, time to nadir and time to recovery from different grades of neutropenia. The predictive performance was also evaluated externally against data in the literature. To this end, the final model was used to simulate a typical ANC-time profile after chemotherapy alone (i.e. in the absence of filgrastim or pegfilgrastim administration), which was then compared visually with mean digitized data derived from a publication with breast cancer subjects [20] .
The effects of continuous and categorical covariates on relevant population model parameters were assessed. Continuous covariates included body weight normalized to 70 kg, and categorical covariates included filgrastim vs. pegfilgrastim, chemotherapy absence vs. presence, population type and specific doses of filgrastim and pegfilgrastim. Effects of categorical covariates were modelled as additive or proportional shifts from a base/reference category, whereas the effects of continuous covariates were modelled using a power function. The relationship between preselected covariates and the predictions of individual model parameters was investigated graphically. The model was then used to test statistically the covariates for which a relationship was found. When statistical criteria supported contradicting decisions, the visual model fits were used to define the final decision on effects of covariates.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [21] , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 [22] .
Results
Model development
Modelling exogenous G-CSF (i.e. filgrastim and pegfilgrastim) is complex owing to their binding to G-CSFR, which makes their disposition dependent on the dynamics of the biological process they affect (i.e. granulopoiesis). Therefore, model development was performed with a gradual increase in complexity and data volume.
Initial results using data from healthy subjects following IV and SC administration found that F SC , K SC , V D , CL D and K D were different between filgrastim and pegfilgrastim. Furthermore, the stimulation of the neutrophil production rate (STM 1 ) was slightly different between the two drugs, and the internalization rate constant (K INT ) was different between the two routes of administration. The scaling factor between the receptor concentration and ANC was fixed to 354 receptors per cell. This value was estimated in a preliminary run and was both highly correlated with the production rate (K P ) and consistent with literature-reported values for cellular receptor density [23, 24] . As there were limited data available for post-IV administration (n = 14 for filgrastim; n = 16 for pegfilgrastim), model development only included data for post-SC administration. In the absence of IV data, the bioavailability (F SC ) was fixed to 1 for filgrastim and estimated for pegfilgrastim (i.e. relative to filgrastim).
Graphical analysis of IIV revealed differences during model development that necessitated certain estimations in the final model. For instance, the clearance for the 300 μg kg -1 pegfilgrastim dose was lower than that for the other doses; K D was slightly different between filgrastim and pegfilgrastim; and STM 2 and K INT were different between healthy subjects and subjects on chemotherapy. In addition, the variance for K CHM correlated with that for CHMSL. When these differences were estimated in the final model, they were found to be statistically significant. Due to the level of statistical significance, as well as the possible physiological relevance, the lower clearance for the 300 μg kg -1 pegfilgrastim dose in healthy subjects (n = 8) and subjects on chemotherapy (n = 4) was introduced in the model, despite the small sample size (n = 12). Of note, the stimulation of neutrophil production (STM 1 ) for filgrastim and pegfilgrastim was significantly different (P = 0.05). However, this difference did not lead to visually better predictions and was not retained in the final model. The value of K C was also challenged, considering that 6 h was either the life span (K C = 1/6 = 0.167 h À1 ) or the half-life (K C = 0.693/6 = 0.12 h À1 ) of neutrophils in the blood. This difference had no significant impact on the objective function; therefore, K C was fixed to 0.12 h À1 in the final reference model, in order to be consistent with the literature.
Covariate analysis
Model evaluation
The pcVPC results demonstrated good predictability for drug concentrations and ANC as a function of time after the first chemotherapy cycle. Sample pcVPC for PK and ANC data in adults are shown in Figures 2 and 3 (Figure 4 ), time to nadir ( Figure 5 ) and time to recovery from neutropenia grades 4 to 3 and 3 to 2 ( Figure 6 ). Collectively, these results demonstrate the predictive performance of the model. Using the parameters from the reference model, a simulation was performed to test the correlation with summary profiles from the literature (Figure 7 ). This comparison demonstrated that the model was able to simulate adequately the ANC-time profile after chemotherapy alone (i.e. without filgrastim or pegfilgrastim administration), despite the fact that this information was not directly available in the database used for modelling. This external evaluation demonstrated feasibility for using the model to derive the chemotherapy effect on ANC. Adequate agreement in trends was predicted by the model and actual data from that study ( Figure 7A) . However, the model appeared to overpredict the nadir in that study population. This is likely to have been due to the differences between the ANC baselines reported in the literature and the baseline ANC predicted by the model, based on analysis datasets. Thus, following baseline normalization, better agreement was observed between model predictions and external literature data ( Figure 7B ). The parameter estimates and associated precisions from the reference model are reported in Table 2 .
Discussion
The US Food and Drug Administration approved the use of filgrastim in 1991 and pegfilgrastim in 2002 for the treatment of CIN [25] . Since approval, regulators have suggested methods for standardizing clinical decisions on the use of exogenous G-CSF mimetics. Despite these guidelines, and owing to differences in regional implementations, the practice of using G-CSF during myelosuppressive therapies is still not standardized [26] . Model-based predictions on neutropenia can help to standardize treatment protocols and inform clinical decisions [27] . The construction of models with biological relevance has been in practice in both the biopharmaceutical and modelling communities. One of the most frequently utilized myelosuppressive models is by Friberg et al. [14] . In this model and its direct variants, chemotherapy induces the killing of proliferative cells, whereas the nonmitotic cells are not affected. A negative feedback on proliferation/maturation rates from the circulating neutrophil counts is described using an empirical function of ANC related to baseline levels and is incorporated into the model to capture the stimulating effect of endogenous growth hormones (mainly G-CSF) on the proliferation rate. However, better physiological understanding of the dynamics and interplay between endogenous G-CSF and neutrophils following chemotherapy would improve the feedback mechanism of the Friberg model and thereby increase its predictive capacity of different G-CSF dosing strategies. Several extensions of the Friberg model have been developed by adding increasingly complex mechanisms and relationships [28] . The inclusion of the effects of G-CSF treatment in the neutropenia model framework is a natural offshoot of the myelosuppression model. The PK of the G-CSFs is typically described using target-mediated drug disposition models [11, 29] . The construction of models that apply the dynamics of neutrophils under the endogenous effects of G-CSF or following treatment with G-CSF mimetics in healthy subjects and cancer patients has been attempted previously [8, 30] . Previously reported models used unbound G-CSF concentrations or the relative change in G-CSF as drivers for effects on ANC dynamics [8, 30] . The current model offers a more indepth, semi-mechanistic physiological understanding of the kinetics of G-CSF derivatives/mimetics and the dynamics of neutrophils.
The structural model developed in the present analysis consisted of four main components that quantified: (i) ANC homeostasis and dynamics; (ii) filgrastim and pegfilgrastim disposition and effects on granulopoiesis; (iii) CIN; and (iv) corticosteroid stimulation of ANC. The effect of filgrastim and pegfilgrastim on ANCs was described by a stimulation of the neutrophil production and maturation in the bone marrow. Consistent with previous models [8, 30] , the current analysis demonstrated that G-CSF concentrations are inversely related to ANC following any type of chemotherapy. This was not unexpected because the effect of neutrophils on filgrastim or pegfilgrastim disposition was based on a drug receptor-binding model, and the turnover of targetcarrying neutrophils (piecemeal degranulation) and the chemotherapy and corticosteroid effects were represented by KPD-type models. Pegfilgrastim 100 µg kg
Figure 4
Example observed and model-predicted nadir in adult subjects from two studies on chemotherapy receiving filgrastim (A) and pegfilgrastim (B For both filgrastim and pegfilgrastim, the value for k tr and estimates for k c , k int and K D , as well as the linear elimination components and distribution volumes, were consistent with estimates from previous G-CSF mimetics ANC dynamics modelling reports [8, [30] [31] [32] . After correction for bioavailability factors (0.65 vs. 1), the volume of distribution (V D /F) was higher (8.3 vs. 3.1 l), and the clearance slightly lower (0.57 vs. 0.83 l h -1 ) for pegfilgrastim compared with filgrastim. This resulted in estimated apparent systemic half-lives of 2.6 h and 10.1 h for filgrastim and pegfilgrastim, respectively. These estimates were in agreement with those reported for both drugs following IV dosing [3, 4] . However, a fourfold increase in the 'apparent half-life' is not unexpected for pegylated proteins [33] and is likely to be due to a much lower renal clearance resulting from the pegylation, as well as the potential for flip-flop kinetics upon SC administration as a result of slow absorption. The estimates of absorption rate constants indicated that pegylation also resulted in a reduced rate of absorption. Body weight was found to be a significant predictor of IIV in V D and CL. The estimated powers were close to the expected allometric value for each parameter. This supports the body weight-based dose in adults and children. The dissociation constant (K D ) of pegfilgrastim (0.096 nM) was also higher than that for filgrastim (0.024 nM), possibly indicating a slightly lower affinity for the G-CSFR. However, in vitro estimates of K D were not different for pegfilgrastim vs. filgrastim. The maximum stimulation of the neutrophil production by filgrastim and pegfilgrastim is estimated to be 7.5 times the basal production. A significantly larger estimate has been reported for the maximum Table 2 Parameter estimates, standard errors and P-values for the filgrastim (FIL) and pegfilgrastim (PEG) PK and ANC model developed using data from healthy subjects and adult cancer patients following the first chemotherapy cycle extent of stimulation in neutrophil production [31] . However, this is not consistent with the current observed data analysed herein. Moreover, other reports reported a maximum stimulation of production by G-CSF derivatives as 3.73, which is highly consistent with the current findings, which were based on a much larger dataset. Additionally, there is no evidence to suggest that the maximum stimulation is different between the two G-CSF derivatives. The maximum stimulation of the transit rate constant of the neutrophils in the bone marrow was slightly lower in subjects on chemotherapy than in healthy subjects (3.9 vs. 5.2), indicating a slightly slower maturation process in subjects on chemotherapy. The internalization rate constant was also lower in subjects on chemotherapy vs. healthy subjects (0.113 h À1 vs. 0.197 h À1 ) but was in the same range as the neutrophil elimination rate constant of 0.12 h À1 .
The large variability in the chemotherapy and corticosteroid effect parameters reflected the differences in treatments and/or sensitivity of the subjects on chemotherapy. As no detailed information on chemotherapy and corticosteroid treatment was available, this could not be further investigated. Previously reported models implemented the effects of corticosteroids as temporary increases in G-CSF production immediately prior to chemotherapy. This mechanism was inspired by a short-lived surge in G-CSF observed following high-dose steroid administration [8] . Such a surge in G-CSF under corticosteroid treatment was not observed in our data, and, thus, the effect of corticosteroids was implemented as being stimulatory to ANC production and maturation. This was supported by the observed data showing a temporary increase in ANC. The lag-time of the corticosteroid effect (16.3 h) seemed to indicate that the corticosteroid treatment had been given about 8 h before chemotherapy. The lag-time of chemotherapy (66 h) indicated a delayed effect at the mitotic cell level, but this might also be an indication that the maturation process in the bone marrow is not a linear function of time.
Of note, some differences in parameter estimates were observed between paediatric and adult subjects. Separate estimations of parameters between adults and children were required (e.g. bioavailability, clearance, neutrophil production rate, dissociation constant, chemotherapy lag-time, magnitude of effect and duration). The differences in model parameters between adults and paediatric subjects on chemotherapy may lie in the differences in the types of chemotherapy treatments between adults and children, and among individual children. In particular, the nontargetmediated disposition of pegfilgrastim in children was typically 45% of that in adults. As the number of children in the analysis was relatively small (n = 16 for filgrastim; n = 36 for pegfilgrastim), these differences should be interpreted with caution and are likely to be highly dependent on the limited data available. Thus, detailed results from modelling children and adults are not included. Additionally, parameter estimates based on multicycle data were highly consistent with the first cycle-derived model described herein.
The semi-mechanistic physiologically relevant model structure integrates all these physiological interacting entities to describe the target-and PD-mediated disposition of filgrastim and pegfilgrastim in relationship with their stimulation of ANC production and maturation rates. Simultaneously, the model was able to capture the killing effect of chemotherapy. The model was also able to capture the magnitude of neutropenia and the duration, as demonstrated by internal and external evaluation with data after chemotherapy alone. In addition, all entities were modelled together, which allowed for discrimination and estimation of the stimulation effects of filgrastim and pegfilgrastim, and the killing effects of chemotherapy, in addition to discerning major covariate effects.
The current model appears to be highly physiologically relevant for the reasons explained above and is based on the largest body of data on G-CSF in healthy subjects and cancer patients. However, adding complexities to the model is limited by the availability of data describing more intricate details on the different precursor cells, states of mitosis or quiescence, involvement of other growth factors, and differential effects of growth factors and chemotherapies on the different stages of cell maturation and production. A systems modelling approach would be more suited to interrogate such data and processes, if or when available [34] .
Conclusions
The current integrated physiologically based semi-mechanistic PK-ANC model successfully characterized the target-and PD- Log-likelihood estimation through importance sampling. Sampling distribution for random-effect parameters was assumed to be t-distribution with five degrees of freedom. ANC, absolute neutrophil count; CI, confidence interval; CV, coefficient of variation; G-CSF, granulocyte colony-stimulating factor ; PK, pharmacokinetic; RSE, relative standard error; SD, standard deviation mediated disposition of filgrastim and pegfilgrastim, the effect of filgrastim and pegfilgrastim on neutrophil dynamics, the magnitude and duration of the chemotherapy effect on granulopoiesis, and the between-subject variability of these effects both in adults and children. The qualified model is useful to simulate the time course of filgrastim and pegfilgrastim, as well as estimate ANC effects in the absence or presence of chemotherapy. The model is also adequate to predict the nadir, time to nadir and time of recovery from neutropenia grades 4 to 3 and 3 to 2 after chemotherapy and upon treatment with filgrastim and pegfilgrastim. Thus, the model can be used to interrogate differences in PK and efficacy, extrapolate to other conditions that cause insults to bone marrow (e.g. myelosuppressive anticancer drugs, myeloablative chemotherapy in the context of bone marrow transplantation, myelosuppressive doses of radiation) and inform different clinically relevant inputs related to dosing decisions for both compounds.
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